TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04265001

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid in the form of hyaluronan sodium 25 mg/100 ml as a mouthwash
Description: Topical mouthwash used three times daily for one week and patients were not allowed to eat or drink for one hour after rinsing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid in the form of hyaluronan sodium 25 mg/100 ml as a mouthwash
Description: Topical mouthwash used three times daily for one week and patients were not allowed to eat or drink for one hour after rinsing.
Study: NCT04553419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cephalexin
Description: Cephalexin capsule: TEVA Cephalexin Cephalexin suspension: LUPIN Cephalexin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Cellulose capsules or suspension
Study: NCT02939352

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real continuous Theta Burst Stimulation
Description: Continuous Theta Burst stimulation delivered

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real continuous Theta Burst Stimulation
Description: Continuous Theta Burst stimulation delivered

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham continuous Theta Burst Stimulation
Description: active sham Continuous Theta Burst stimulation delivered
Study: NCT04406740

Intervention type: DEVICE
Intervention: Novel QTOF Device
Description: The QTOF consists of an electrical stimulator that is just like the stimulator in the traditional TOF devices that are commonly used (both accelerometric and EMG-based), combined with a novel sensor that sticks to the belly of the muscle being measured (most commonly the adductor pollicis, the thumb muscle in the palm of the hand).
Study: NCT00124293

Intervention type: DRUG
Intervention: activated recombinant human factor VII
Study: NCT01666938

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diabetes Education Group
Description: Diabetes Education Group: Diabetes Education for four month, one time per week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telephone Counseling
Description: Telephone counseling: 12 phone calls for four months about physical activity. During the first and second month, was done four phone calls each month. During the third and fourth month, was done two phone calls per month.
Study: NCT02939352

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham continuous Theta Burst Stimulation
Description: active sham Continuous Theta Burst stimulation delivered
Study: NCT00726245

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRGF
Description: 3-6mg IM (to area of muscle tear)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3cc IM of physiological saline
Study: NCT02866981

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observation
Study: NCT02186028

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Vit D 400 IU vs. Vit D 200 IU

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Vit D 400 IU vs. Vit D 200 IU
Study: NCT03537833

Intervention type: OTHER
Intervention: pemetrexed-related hematological toxicity
Description: hematological toxicity will be found on biologic data the day or the day before chemotherapy. Classification will based on NCI-CTCAE criteria

Intervention type: OTHER
Intervention: pemetrexed-related hematological toxicity
Description: hematological toxicity will be found on biologic data the day or the day before chemotherapy. Classification will based on NCI-CTCAE criteria
Study: NCT02318199

Intervention type: PROCEDURE
Intervention: Anesthesia recovery after intracranial surgery
Description: Intracranial surgery for brain tumor, traumatic brain injury, intracranial hemorrhage, subarachnoid hemorrhage and infection.

Intervention type: PROCEDURE
Intervention: Anesthesia recovery after intracranial surgery
Description: Intracranial surgery for brain tumor, traumatic brain injury, intracranial hemorrhage, subarachnoid hemorrhage and infection.
Study: NCT00607893

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Positive Airway Pressure (CPAP)
Description: Participants will use the higher pressure CPAP, as determined by an in-laboratory attended titration study, every night for 12 weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham CPAP
Description: Participants will use the lower pressure CPAP every night for 8 weeks.
Study: NCT01559168

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UpholdTM LITE placement
Description: Uphold TM LITE mesh is used for the surgical correction of pelvic organ prolapse.
Study: NCT03979313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI8897
Description: Anti-RSV monoclonal antibody with an extended half-life

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Commercially available 0.9% (w/v) saline
Study: NCT03977480

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hemay007
Description: Hemay007 will be orally administered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hemay007
Description: Hemay007 will be orally administered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hemay007
Description: Hemay007 will be orally administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04413045

Intervention type: OTHER
Intervention: Prevalence of COVID-19
Description: All COVID-19 cases to be admitted in the assigned hospital with positive results of nasopharyngeal swab for SARS-CoV-2 during one-month duration.
Study: NCT05522478

Intervention type: DEVICE
Intervention: Fall risk
Description: Fall risk, static postural balance and sensorimotor integration were assessed using the Biodex Balance System.

Intervention type: DEVICE
Intervention: Fall risk
Description: Fall risk, static postural balance and sensorimotor integration were assessed using the Biodex Balance System.

Intervention type: DEVICE
Intervention: Fall risk
Description: Fall risk, static postural balance and sensorimotor integration were assessed using the Biodex Balance System.
Study: NCT03437967

Intervention type: DEVICE
Group type: OTHER
Intervention: LightForce EXPi
Description: LASER photobiomodulation therapy of 15-25 watts of coherent infrared light to affected area for 10 minutes using wand-type probe.

Intervention type: DEVICE
Group type: OTHER
Intervention: LightForce EXPi
Description: LASER photobiomodulation therapy of 15-25 watts of coherent infrared light to affected area for 10 minutes using wand-type probe.
Study: NCT04523376

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS
Description: Peripheral blood stem cells from closely matched unrelated donors will be processed using the CliniMACS device to remove TCRalpha/beta T cells and B cells, in accordance with the Investigator Brochure and Technical Manual following the laboratory standard operating procedures (SOPs) and using aseptic technique

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS
Description: Peripheral blood stem cells from closely matched unrelated donors will be processed using the CliniMACS device to remove TCRalpha/beta T cells and B cells, in accordance with the Investigator Brochure and Technical Manual following the laboratory standard operating procedures (SOPs) and using aseptic technique
Study: NCT00865605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Halobetasol Propionate 0.05% Ointment, single exposure
Description: A: Other Subjects received Alpharma/Purepac USHP formulated products

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ultravate® 0.05% ointment, single exposure
Description: Subjects received Bristol-Myers Squibb Company formulated products
Study: NCT03228082

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home Blood Pressure Monitoring (HBPM)
Description: Home blood pressure monitoring using the Withings Wireless BP monitor. Patients will be asked to measure their blood pressure twice daily for 7 consecutive days. This will be repeated for every month for 1 year.
Study: NCT03246178

Intervention type: OTHER
Group type: OTHER
Intervention: MSD-HSCT
Description: 1. Conditioning regimens: (A) Patients had SAA and PNH, or heavy transfusion (RBC≥25U), or failed rabbit ATG therapy, and received 0.8 mg/kg/6h busulfan (days -7 to -6), 30mg/m2/day fludarabine (days -5 to -2), 25 mg/kg/day cyclophosphamide (days -5 to -2) and 2.5 mg/kg/day r-ATG (days -5 to -2). (B) The other patients with SAA or VSAA received same procedure but without busulfan;~2. Allogeneic HSC infusion: Doner BM cells were harvested to achieve a target mononuclear cell count (MNC) of 2-4 × 108 per kilogram of recipient weight. The target MNC from PB was 4-6× 108 per kilogram of recipient weight;~3. Prophylaxis and treatment of GVHD: GVHD prophylaxis consisted of intravenous CSP 2-3 mg/kg/day in divided doses beginning on the day before transplantation (day -5) and the target concentration was adjusted to 150-250 ng/ml. The oral MMF dose was 20 mg/kg/day from day -1 and was tapered off after 1 months if no aGVHD was observed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HFD-HSCT
Description: 1. Conditioning regimens: (A) Patients had SAA and PNH, or heavy transfusion (RBC≥25U), or failed rabbit ATG therapy, and received 0.8 mg/kg/6h busulfan (days -7 to -6), 35mg/m2/day fludarabine (days -5 to -2), 25 mg/kg/day cyclophosphamide (days -5 to -2) and 2.5 mg/kg/day r-ATG (days -5 to -2). (B) The other patients with SAA or VSAA received same procedure but without busulfan;~2. Allogeneic HSC infusion: Doner BM cells were harvested to achieve a target mononuclear cell count (MNC) of 2-4 × 108 per kilogram of recipient weight. The target MNC from PB was 4-6× 108 per kilogram of recipient weight;~3. Prophylaxis and treatment of GVHD: GVHD prophylaxis consisted of intravenous CSP 2-3 mg/kg/day in divided doses beginning on the day before transplantation (day -5) and the target concentration was adjusted to 200-300 ng/ml. The oral MMF dose was 20 mg/kg/day from day -3 and was tapered off after 2 months if no aGVHD was observed.
Study: NCT03617588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gallium-68 THP-PSMA
Description: Subjects will undergo a Gallium-68 THP-PSMA scan in addition to standard of care monitoring. The results of this scan may influence the patient management plan.
Study: NCT02398344

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS active
Description: Transcranial direct current stimulation (tDCS) the active tDCS and placebo will be applied to the temporal cortex (T3) associated Cardiac Frequency Variability (HRV).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS Sham
Description: Active stimulation application time or placebo 20 minutes. In all sham stimulation, electrode placement procedures will also be performed like the procedures with anodic tDCS, the left and right temporal cortex, however, the stimulator is turned on for 30 seconds only, and the patient will be told that he will feel a slight initial tingling, but it will reduce, disappear or remain during the 20 minutes of application. Thus, individuals will feel it initially, but receive no stimulation in the remaining time. This procedure is a valid form of control in challenge studies transcranial direct current ³³. The equipment itself has a sham configuration.
Study: NCT01896024

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motive-oriented therapeutic relationship/Plan Analysis
Study: NCT03868254

Intervention type: DEVICE
Intervention: XEN Group
Description: Chart review was conducted in participants with open angle glaucoma who underwent placement of the implant XEN 45 Gel Stent as a standalone procedure from 1 January 2014 to 1 October 2015.
Study: NCT02934646

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic treatment
Description: Passive/active elbow mobilizzation provided by NEUROExos Elbow Module Robotic device
Study: NCT02169232

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Videolaryngoscope

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fiberoptic
Study: NCT03868254

Intervention type: PROCEDURE
Intervention: Phacoemulsification
Description: Chart review was conducted in participants with open angle glaucoma who underwent placement of the implant XEN 45 Gel Stent in combination with phacoemulsification (Phaco) from 1 January 2014 to 1 October 2015.
Study: NCT01253642

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy of Prostate
Description: Undergo transrectal ultrasound (TRUS) guided prostate biopsy OR image-guided (CT or ultrasound) core bone or soft tissue biopsy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenelzine Sulfate
Description: Given PO
Study: NCT00867516

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALD518
Description: Two doses of ALD518, each given in an infusion of normal saline, IV over 1 hour, at Weeks 1 and 8

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALD518
Description: Two doses of ALD518, each given in an infusion of normal saline, IV over 1 hour, at Weeks 1 and 8

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALD518
Description: Two doses of ALD518, each given in an infusion of normal saline, IV over 1 hour, at Weeks 1 and 8

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Infusion without ALD518'
Description: 250 cc Normal saline IV over one hour Weeks 1 and 8.
Study: NCT02310412

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INTERCEPT treated platelets

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INTERCEPT treated platelets
Study: NCT01835821

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: prosthetic crowns
Description: prosthetic crowns
Study: NCT00967317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Auris-Sedina
Description: Drip 2 drops of the medication with the head tilted and protect with a cotton swab. Repeat the process one at a time until the pain relief. Continue the administration of medication every 3 hours until the pain ceases.~The medication should be used for a maximum of 3 days when they should return to the doctor.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Otosynalar®
Description: Drip 3 drops in the ear 2 times a day. The medication should be used by more than 3 days after which the patient must return to the doctor.
Study: NCT02320006

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: acupuncture
Description: For RN4、CV6 CV3 and EX-CA1, needles will be inserted vertically to the abdominal muscles. The acupuncturist can feel resistance from the tip of the needle when touching the muscles and continues to insert it to a depth of 2-3 mm and stops. For ST36 and SP6, needles will be inserted vertically to a depth of 25 mm. The needles will be manipulated with an even lifting and twisting method three times to achieve the sensation of deqi.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: acupuncture
Description: For RN4、CV6 CV3 and EX-CA1, needles will be inserted vertically to the abdominal muscles. The acupuncturist can feel resistance from the tip of the needle when touching the muscles and continues to insert it to a depth of 2-3 mm and stops. For ST36 and SP6, needles will be inserted vertically to a depth of 25 mm. The needles will be manipulated with an even lifting and twisting method three times to achieve the sensation of deqi.
Study: NCT04130321

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Camu camu
Description: 3 capsules of camu camu powder (500 mg / capsule) daily during 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 capsules of placebo daily during 12 weeks
Study: NCT03306667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FYU-981
Description: Oral single dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FYU-981
Description: Oral single dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FYU-981
Description: Oral single dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FYU-981
Description: Oral single dosing
Study: NCT02494960

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The brief smoking cessation AWARD model
Description: * Ask whether or not the patient currently smokes~* Warn the patients that at least one out of two smokers will be killed by smoking. Recent research shows that two out of three smokers will be killed by smoking. The 10-20-second script could be like 'I warn you that smoking can kill you by many serious diseases and that your chance to be killed prematurely by smoking is about 50% to 67%.~* Advice the patients to quit now or as soon as possible because quitting can reduce the excess risks substantially.~* Refer the patients to a smoking cessation clinic or call telephone quitlines (if available) as soon as possible, emphasizing that smoking cessation counsellors are caring and helpful.~* Do it again: Repeat the intervention among smokers who fail to quit or relapse, and encourage them to try to quit again.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The brief smoking cessation AWARD model
Description: * Ask whether or not the patient currently smokes~* Warn the patients that at least one out of two smokers will be killed by smoking. Recent research shows that two out of three smokers will be killed by smoking. The 10-20-second script could be like 'I warn you that smoking can kill you by many serious diseases and that your chance to be killed prematurely by smoking is about 50% to 67%.~* Advice the patients to quit now or as soon as possible because quitting can reduce the excess risks substantially.~* Refer the patients to a smoking cessation clinic or call telephone quitlines (if available) as soon as possible, emphasizing that smoking cessation counsellors are caring and helpful.~* Do it again: Repeat the intervention among smokers who fail to quit or relapse, and encourage them to try to quit again.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo intervention
Description: Advice the smokers to eat vegetables, and engage in regular physical activities, and offer the smokers a card which contains information about the benefits of eating vegetables and a pictorial information leaflet which shows the recommended amount of vegetables and fruits an adult should eat a day
Study: NCT02908126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Oxytocin drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Oxytocin drug
Study: NCT00938678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim Hospira
Description: Subjects in both treatment groups will have safety assessments and will be followed for all adverse and serious adverse events.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neulasta (Amgen)
Description: Subjects in both treatment groups will have safety assessments and will be followed for all adverse and serious adverse events.
Study: NCT03410628

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: gammaCore
Description: Non-invasive vagal nerve stimulator
Study: NCT01963195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib
Description: Patients can accept the treatment with Icotinib (250/375/500mg tid) until disease progression or unacceptable toxicities occurred. The overall study period takes about 24 months
Study: NCT03753685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: X-396(Ensartinib) Capsule
Description: All consented, enrolled, eligible patients receive X-396 capsules, 225mg once daily.
Study: NCT03558542

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cardiopulmonary rehabilitation plus neurorehabilitation
Description: Patients with stroke will undergo an accompanying structured cardiopulmonary rehabilitation program along with a neurorehabilitation program
Study: NCT03974386

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: oXiris blood purification set
Description: Continuous venovenous hemofiltration and adsorption (CVVHA) with oXiris filter for up to 72 hours if required. The filter will be replaced every 24 hours. The setting of CVVHA is as follows: blood flow rate 200 mL/min, replacement fluid rate 2000 mL/hr, pre-dilution 50% and post-dilution 50%. If continuous renal replacement therapy is indicated after 72 hours, conventional hemofiltration filters will be used.
Study: NCT05448040

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Socket preservation
Description: Tooth extraction and preservation with a biomaterial

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Socket preservation
Description: Tooth extraction and preservation with a biomaterial
Study: NCT00731419

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SEMS
Description: Comparing plastic and metal stents

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SEMS
Description: Comparing plastic and metal stents
Study: NCT00671034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calaspargase Pegol-mknl
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV, IT, PO, or SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Given IV, IT, PO, or SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daunorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO or IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Given PO or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01451658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propranolol
Description: Starting from 20 mg daily, titrated weekly to decrease heart rate more than 25 % of baseline, administrated during the whole study period
Study: NCT01666938

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telephone Counseling
Description: Telephone counseling: 12 phone calls for four months about physical activity. During the first and second month, was done four phone calls each month. During the third and fourth month, was done two phone calls per month.